NICE climbdown over anti-flu drug Relenza

Posted on September 1st, by editor in Caring Times. No Comments

Elderly people in care homes are among those who will benefit from a change of heart by the National Institute of Clinical Excellence (NICE) with regard to the anti-flu drug Relenza. NICE reversed a decision last year not to make the drug available on the NHS, and now says that people over 65, those with respiratory disease, those with lowered resistance to infection (for example, those with diabetes) should have access to the drug when flu is “circulating in the community”. Official guidelines suggest that this occurs when 50 to 400 cases of flue occur per 100,000 GP consultations. Vaccination remains the mainstay of preventing flu in all those at risk, but Relenza will, in some patients, reduce the chances of developing flu, and may reduce the length and severity of the illness.

Comments are closed.

Latest blog posts

End of life care – care homes can do it well

By guest blogger Professor Keri Thomas,

Clinical director, National GSF Centre for End of Life Care

News that care homes could, based on current trends, overtake...

The DTOCs dashboard dilemma

By guest blogger JEF SMITH

The Department of Health refers to delayed transfers of care – the issue of people not being able to move...

From where I stand . . .

By Caring Times editor GEOFF HODGSON

A group of residents’ families have criticised the Care Quality Commission’s refusal to review the ‘good’ rating it awarded to...